Back

Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)

30 August 2024 (12:00 - 12:50)
Organised by: Logo
Congress Presentation Part of: Drug therapy for heart failure: what is new? Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Steven Coombs

Brighton & Sussex University Hospitals N H S Trust, Brighton (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF
Doctor H. Lu (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
Professor M. Crespo-Leiro (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED
Doctor R. Aggarwal (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Long-term follow-up of the TRED-HF trial
Miss L. Cheng (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy for heart failure: what is new?

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin for heart failure with reduced ejection fraction: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study
thumbnail
Congress Presentation
Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy
thumbnail
Congress Presentation
Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources